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Epidemiological Measures of Risk of Malaria
J. Kevin Baird, Michael J. Bangs, Jason D. Maguire, and Mazie J. Barcus
1. Introduction
Estimates of the risk of infection by the parasites that cause malaria govern deci-
sions regarding vector control, chemoprophylaxis, therapeutic management, and clini-
cal classifications of immunological susceptibility to infection. Gauging the risk of
malaria represents a critical step in its management and the investigation of its conse-
quences. The term malariometry is applied to the numerical measure of risk of malaria
in communities (9). Many approaches have been developed and applied to
malariometry, but no single method stands out as universally applicable. Instead, indi-
vidual measures of risk must be suitable for specific questions posed in the context of
what may be practically measured. For example, passive surveillance provides a supe-
rior measure of risk where the infrastructure of diagnosis and reporting is well devel-
oped and the risk of infection relatively low, e.g., in the United States, where conducting
active cross-sectional surveys would yield little useful information at great cost. Active
surveillance for cases is suited to areas with relatively high risk, unreliable diagnostic
capabilities and inadequate reporting infrastructure. This chapter strives to catalog
measures of risk of malaria and define their utility in the context of local parameters of
endemicity, infrastructure, and intent of inquiry.
The risk of malaria is highly dependent on interactions between the host, parasite,
mosquito vector, and environment, a relationship known as the epidemiologic triad of
disease. Changes in any one of these elements may profoundly impact risk of infection.
Measures of risk of malaria may be broadly classified as either indirect or direct. Indi-
rect measures gauge risk through surrogate markers of risk of infection such as rainfall,
altitude, temperature, entomological parameters, spleen rates, antibody titers, or pat-
terns of antimalarial drug use in a community. Direct measures of risk depend on diag-
noses of malaria (clinical or microscopic) and their relationship to a variety of
denominators representing classes of persons at risk over some unit of time. In general,
indirect measures apply data conveniently at hand to estimate risk of malaria. By con-
trast, direct estimates of risk often require deliberate effort to collect data for the sole
purpose of gauging risk of malaria.
An area supporting active malaria transmission is termed endemic. Transmission of
infection may be unstable or stable, the primary difference being a fluctuating low to
high incidence versus a consistently high incidence over successive years.
Malariologists have long graded endemic malaria according to risk of infection as reflected
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in the proportion of children and adults having enlarged spleens (spleen rate, see below).
However, these terms have evolved into a more general use and are routinely applied in the
absence of supporting spleen rate measures. The following terms have been used to empiri-
cally gauge regional risk according to criteria described by Bruce-Chwatt (9):
1. Hypoendemic: Little transmission, and the effects of malaria on the community are unimportant.
2. Mesoendemic: Variable transmission that fluctuates with changes in one or many local
conditions, e.g., weather or disturbance to the environment.
3. Hyperendemic: Seasonally intense malaria transmission with disease in all age groups.
4. Holoendemic: Perennial intense transmission with protective clinical immunity among adults.
2. Indirect Estimates of Risk of Malaria
2.1. Environmental (Rainfall, Altitude, Temperature)
Transmission of malaria requires mosquito vectors in the genus Anopheles. These
insects exhibit exquisite sensitivity to the environmental parameters of temperature
and humidity. Thus, rainfall, altitude, and temperature govern the activity and abun-
dance of anopheline mosquitoes and the transmission of malaria. Within ranges of tem-
perature (20–30°C) and humidity (>60%) that vary for each vector species, the
mosquito survives and is capable of transmitting malaria. When the limits of tempera-
ture and humidity tolerance are exceeded, the vectors die, and the risk of malaria evapo-
rates. Variations of temperature and humidity within the viable range for mosquitoes
can also affect the duration of sporogony, the time required for development of the
parasite in the mosquito after taking a bloodmeal from an infected human so that a new
host can be infected. Cooler temperatures generally prolong sporogony, decreasing the
period of infectivity. High relative humidity increases mosquito life-span, so that each
infective mosquito can infect more hosts. The risk of transmission by anophelines, how-
ever, depends on an available pool of infectious humans so that even in a favorable envi-
ronment with the appropriate vector, transmission cannot be sustained without adequate
numbers of already infected humans. Conditions perfectly suitable for anopheline sur-
vival allow seasonably abundant mosquito populations in the United States, but infection
is rare because of the lack of infectious humans in the region.
2.2. Entomological
Chapter 1 details the use of the entomological inoculation rate as a measure of risk
of infection. The following terms have been used to describe risk of malaria according
to entomological criteria:
1. Human landing rate = anophelines captured/person-night.
2. Infected mosquito = oocysts in stomach wall by dissection.
3. Infective mosquito = sporozoites in salivary gland by dissection.
4. Sporozoite rate = infective anophelines/anophelines captured.
5. Entomological inoculation rate = human landing rate × sporozoite rate.
= infective mosquito bites/person-night.
2.3. Clinical
2.3.1. Spleen Rate
The spleen rate is the proportion of people in a given population having enlarged
spleens expressed as a percentage. The relationship between malaria and the spleen
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rate has served as an indirect marker of risk of malaria long before plasmodia were
known as the cause (Dempster introduced the method in India in 1848). Chronic expo-
sure to malaria causes spleen enlargement. Thus, the percentage of people having
enlarged spleens and the degree of enlargement correlate with risk of infection in a
community. The WHO has classified endemicity as gauged by spleen rate as shown in
Table 1.
Important caveats complicate this convenient estimate of risk. Under conditions of
epidemic malaria, where risk of infection may be very high, spleen rates may be close
to nil because exposure is acute rather than chronic. The spleen rate is useful as a
relative measure of risk only where stable malaria prevails. The distinction between
hyperendemic and holoendemic on the basis of spleen rate in adults, developed on the
basis of observations in sub-Saharan Africa, does not appear to hold true on the island
of New Guinea where adults consistently have enlarged spleens in the face of
holoendemic malaria.
A secondary estimate of risk utilizing spleen measurements is the average enlarged spleen
(AES). The AES represents the mean Hackett score derived from a sample of enlarged
spleens. Table 2 describes grading of spleen enlargement on the basis of palpation.
Spleens with Hackett scores of zero are not included in the calculation of AES. A
higher AES between two sites with comparable spleen rates may be interpreted as con-
sistent with higher risk. A recent malariometric survey in Papua New Guinea found
that, although spleen rates did not vary with altitude for children less than 10 yr of age,
AES decreased with increasing altitude, closely paralleling altitude specific prevalence
of malaria (4).
Table 1
WHO Criteria for Classification of Endemicity by Spleen Rates
Endemicity Children aged 2–9yr (%) Adults (>16 yr)
Hypoendemic 0–10 No measure
Mesoendemic 11–50 No measure
Hyperendemic >50 “High” (>25%)
Holoendemic >75 “Low” (<25%)
Table 2
Criteria for Scoring Spleen Sizea
Score Description of spleen as measured with subject in recumbent position
0 Normal, not palpable
1 Palpable below costal margin on deep inspiration
2 Palpable below costal margin but not beyond midpoint between costal margin and
umbilicus
3 Palpable below limits for score of 2 but not beyond umbilicus
4 Palpable below umbilicus but not beyond midpoint between umbilicus and
symphisis pubis
5 Palpable beyond limits for score of 4
aAES = Σ(Hackett scorei × ni)/N, where Hackett scores of 1 through 5 are included. ni = number of
spleens measured with a given Hackett score. N = n1 + n2 + n3 + n4 + n5 (total number of non-Hackett 0
spleens measured)
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2.3.2. Serology
Serological tests have been applied to demonstrate exposure to infection among
individual subjects. Unfortunately, no serological test reliably assesses either degree of
naturally acquired immunity or the extent of exposure in individuals. Risk of exposure
among groups, however, may be assessed by serological analyses. Detection of anti-
bodies to the circumsporozoite protein (CSP) in European travelers returning from
malarious areas suggests that anti-CSP antibodies can serve as an indicator of the rela-
tive risk of infection in travelers to specific regions (5–7). The prevalence of antibodies
to malaria antigens such as CSP, merozoite surface antigen (MSA), and erythrocytic
stage antigens has also served as an indirect indicator of risk of infection (2,8) and in
some studies correlates with spleen rates (8), prevalence of positive smears (1,8), and
parasite density (2). Serological assays may also be useful in assessing risk in regions
with recent increases in transmission during epidemics or with declining transmission
during eradication efforts (9–11). However, no currently available serological assay
system can reliably serve as a quantitative measurement of exposure.
3. Direct Estimates of Risk of Malaria
3.1. Passive Surveillance
3.1.1. Passive Case Detection
Passive case detection (PCD) is the detection and reporting of malaria cases
restricted to people seeking treatment for illness at a health post, clinic, or hospital. The
PCD is reported as simply the number of cases treated. The PCD proportion, or ratio of
malaria cases to some defined total (hospitalizations, febrile illnesses, deaths), is often
used to gauge the burden of illness caused by malaria relative to all other causes defin-
able in the setting from which those data were collected. This is often called the PCD
rate, although it is actually a proportion. The quantitative value of the PCD rate varies
according to the rigor of diagnostic procedures and the likelihood of malaria para-
sitemia masking some other underlying cause of illness (see Subheading 3.2.8.). The
availability of reporting health-care delivery facilities also impacts interpretation of
PCD data. PCD data are used to gauge risk in communities with the assumption that
virtually all infections prompt seeking of treatment at a reporting facility.
In a setting where malaria is reported on the basis of microscopically confirmed
infection, and the proportion of fevers caused by malaria is relatively low, the PCD rate
may serve as a reliable estimate of risk of malaria relative to other febrile illnesses in
the community. In general, this scenario is true where malaria is hypo- to mesoendemic
and health-care providers are more likely to report malaria on the basis of diagnostic
criteria that exclude other more common causes of febrile illness. In this scenario, the
reported PCD proportion may carry good sensitivity and specificity.
The PCD proportion as a measure of risk is less reliable where malaria is hyper- to
holoendemic. This problem stems from three important features specific to heavily
endemic areas. First, because malaria dominates as a cause of febrile illness, health-
care providers tend to make presumptive diagnoses of malaria in patients presenting
with fever. Thus, other causes of febrile illness are often erroneously classified as
malaria so that the specificity of the PCD proportion may be extremely low. Second,
because self-treatment often relieves symptoms, the true burden of malaria in the com-
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munity may be underreported. Finally, naturally acquired immunity in hyper- to
holoendemic regions leaves most infections unnoticed at treatment facilities.
The PCD totals may be analytically applied in a variety of ways. If the PCD total is
believed to have captured most infections in the community, then monthly or annual
PCD case totals may be divided by the mid-interval population of the areas served by
the reporting facilities to define incidence of infection.
Incidence of malaria = malaria PCD total/mid-interval population/unit time
More often, a PCD proportion is applied as a direct measure of the contribution of
malaria to febrile disease in communities expressed as a percentage.
PCD proportion = (malaria cases/patients seeking care for febrile illness) × 100
3.1.2. Annual Parasite Incidence
The number of malaria cases per 1000 population per year is called the annual para-
site incidence, or API. The API represents the most broadly applied measure of risk of
infection. Many health authorities rely upon the API as the core measure of risk of
infection. The statistic is often used as the basis for comparing risk between communi-
ties, districts, provinces, and nations. The means of deriving the numerator for the API,
“cases of malaria”, varies a great deal. Comparisons of risk based on the API demand
consideration of the sources and case definitions; for example, clinical diagnosis ver-
sus smear-confirmed diagnosis for reported total cases. The API numerator often rep-
resents a hybrid of PCD and active surveillance methods (see below), and the relative
contributions of each impact interpretation of the API.
Annual parasite incidence = reported infections/1000 person (mid-year)/year
A statistic used to help interpret the API is the annual blood examination rate, or ABER.
This is the number of blood films examined per 1000 population. The ABER reflects the
degree of diagnostic effort made to identify malaria. For example, between two locations
having comparable API estimates, the location having the lower ABER may be consid-
ered higher risk because less effort produced an equal density of infections.
Annual blood examination rate = blood film exams/1000 person (mid-year)/year
3.2. Active Surveillance
3.2.1. Active Case Detection
Systematic screening of communities for people with fever and examination of blood
films collected from them is called active case detection (ACD). The analytical appli-
cation of infections discovered by ACD varies. The data collected by ACD may be
applied as follows:
Fever rate = (people with fever/people examined for fever) × 100
Malaria among fevers rate = (people with malaria/people with fever) × 100
These estimates serve as measures of the prevalence of fever in the community at
sampling and the proportion of fevers likely caused by malaria, respectively. Health
officers often use ACD to monitor the progress of control efforts within specific areas,
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but also include these detected cases into the numerator for API. Thus, the vigor of case
detection impacts on the API. In this sense, the importance of interpreting the API in
the context of ABER may be appreciated.
3.2.2. Active Case Survey
The primary distinction between active case survey (ACS) and ACD is sampling that
does not exclude people without fever. Whereas ACD estimates the prevalence of fever
and the proportion of fevers caused by malaria, ACS measures the prevalence of para-
sitemia independently of fever. The ACS may be the best approach to assessing risk of
infection in communities where parasitemia often occurs without fever, that is, where
malaria is hyper- to holoendemic. The survey includes recording both febrile and afebrile
(or apyrexic) malaria cases. The analytical application of ACS may include the following:
Point prevalence of malaria = (people with parasitemia/people examined) × 100
Febrile malaria rate = (people with febrile malaria/people with malaria) × 100
Point prevalence refers to the ratio of parasitemic individuals to the total number of
individuals examined at a single point in time. This provides an estimate of risk by
indicating the number of people infected at any given time with higher prevalence
indicating higher rates of transmission. However, for diseases like malaria that may be
seasonal in some locations, the point prevalence in June might not be a good estimator
of risk for an individual traveling to the area in November.
3.2.3. Gametocyte Rate
Analysis of point prevalence data often includes specific designation of the preva-
lence of gametocytemia in study subjects, the carriage of sexual stage parasites that can
be transferred to feeding mosquitoes to complete the life cycle and allow new infec-
tions of human hosts. In highly endemic areas where immunity to disease often devel-
ops, such individuals are frequently asymptomatic and remain undiagnosed and
untreated, serving as reservoirs for new infection in the community. Because
gametocytemia declines with increasing age in malaria endemic regions (1,12), game-
tocyte rates in young children may serve as an indicator of risk, particularly when
comparing gametocyte rates between two different locations.
3.2.4. Period Prevalence
Compared to point prevalence, period prevalence may better reflect risk for persons
who will be exposed to infection over an extended period. This may be especially true
where risk fluctuates appreciably. Whereas point prevalence addresses the question of
whether a person currently has malaria, period prevalence addresses the question of
whether that subject had malaria at any time during the period under investigation.
This serves as a measure of the probability that an individual in a defined population
will be a case at any given time over a defined period. The numerator of this estimate
includes both newly incident cases (see below) and cases that may have developed
before the survey was initiated. The time of onset of infection may not be known,
especially in endemic regions where some subjects may be asymptomatic and remain
undiagnosed. Thus, incident cases and prevalence may not be distinguishable. Assum-
ing a stable population over time, period prevalence is calculated as follows:
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Period prevalence = (people with malaria at start of period + new cases of malaria during
period)/population under study) × 100
Period prevalence requires identifying a sample of individuals from a population,
screening each of them for malaria on enrollment, and systematically repeating malaria
smears during the defined period in order to identify new cases. Multiple infections
among any given individual allows the possibility of a period prevalence of >100%.
The greatest limitation with period prevalence is the fact that many population totals
are dynamic. The migration of people, and other important changes like mass drug
administration, chemoprophylaxis, or any other intervention that alters the number of
people at risk, makes the drawing of meaningful statistical inference from measures of
period prevalence difficult. In many instances, the effort required to define period
prevalence would be better spent measuring incidence, which provides much less
ambiguous measures of risk (see Subheading 3.3.).
3.2.5. Cumulative Incidence
Cumulative incidence (CI) represents the probability or proportion having malaria
or a specific outcome of infection, for example, cerebral malaria, relapse, death, or
chemotherapeutic failure over defined intervals. Cumulative incidence is often referred
to as an “attack rate,” even though the estimate represents a proportion rather than a
true rate. The measurement of CI requires a prospective study of people free of infec-
tion at the outset. These may be uninfected people newly arriving in a malarious area or
people cured of malaria immediately before the observation period. The number of
new infections is divided by the number of people at risk, expressed in the context of
the period of observation. For example, if one follows 100 people for 10 weeks and 25
get malaria, then the 10-week cumulative incidence of malaria is 25%. More often,
larger populations are followed for longer periods, and the estimate may be compli-
cated by losses to follow-up, migration, or death by other causes.
When individual follow-up times vary for study subjects, a convenient means of
calculating cumulative incidence is the actuarial method (also called life table). This
approach takes into account the loss of individuals from the study population in the
denominator by presuming that the mean withdrawal time occurred at the midpoint of
the surveillance interval. For example, in a 1-yr study of malaria with monthly inter-
vals of observation, all subjects lost to follow-up would be assumed to have done so at
the midinterval, that is, 2 wk. This approach conveniently averages person-time losses
across the interval. This is especially useful when such losses are likely, for example,
the occurrence of vivax malaria among subjects recruited to gauge the incidence den-
sity of falciparum malaria. The actuarial method for estimating CI is as follows:
Cumulative incidence = attack rate (%) over a defined period
Cumulative incidence (actuarial) = incident cases/[population at start of study – (number of
withdrawals/2)]
3.2.6. Incidence Density
Incidence density of malaria estimates the risk of infection in a population expressed
as a true rate; that is, the number of new infections per unit person- time. This estimate
requires a cohort of people who are free of infection and prospectively followed over a
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defined period. This is most often accomplished by giving radical curative therapy
before the follow-up phase, but newly arrived migrants into malarious areas may also
provide a suitable cohort without radical cure. Incidence density is calculated simply
as the number of new infections divided by the sum of person-time at risk. People lost
to follow-up contribute person-time to the denominator up to the point of loss. Their
contribution should not be counted for the full period of the study. For example, if one
follows 100 subjects for 52 wk and 25 become infected, the incidence density is 25
infections per 100 person-years, or 0.25 infections per person-year, assuming each
individual contributed 52 wk of follow-up time. This overly simplistic example assumes
no losses to follow-up. However, a subject infected at wk 2 contributes only 2 wk of
person-time to the denominator, not 52. Assume that infections occur evenly over the
52 wk and that approximately one infection occurs every 2 wk. In this scenario, losses
in person-time at risk due to infection outcomes amount to 650 person-weeks, or
12.5 yr. Taking these losses into account, the incidence density would be estimated
at 25 infections/87.5 person-years, or 0.29 infections/person-year. Further, assume
that 20 people were lost follow-up at anywhere from wk 1 to wk 51 of the observa-
tion period, yielding a total loss of 12.5 person-years at risk. Thus, the true incidence
density in the hypothetical cohort would be estimated as 25 infections per 75 person-
years, or 0.33 infections/person-year (or everyone experiencing, on average, an in-
fection once every 3 yr).
Incidence density = infections/person-year at risk
3.2.7. Attributable Risk
Attributable risk (or risk difference) represents an estimate of the risk of disease that
may be attributed to a specific exposure. In its simplest form, it is the additional amount
of disease in those exposed over the background amount of disease in the unexposed
population and is given by:
AR = Ie – Iu
where Ie is the incidence in the exposed population and Iu is the incidence in the
unexposed population.
In conducting malaria studies in transmission areas, it is difficult to reliably differ-
entiate between reinfection and recurrent parasitemia following therapy. The attribut-
able risk statistic, calculated by subtracting the coincident incidence rate for a given
population from the rate of recurrent parasitemia, estimates the rate of therapeutic fail-
ure. The efficacy of standard mefloquine therapy against uncomplicated Plasmodium
falciparum infections was evaluated in children aged 6 to 24 mo in the Kassena-
Nankana District of northern Ghana, West Africa. The incidence of late recrudescence,
or therapeutic failure, was calculated as the difference between the incidence of recur-
rent parasitemia during wk 3 and 4 after mefloquine therapy and the known attack rate
of malaria in the region for the cohort. The incidence of recurrent parasitemia at d 28
was 6.3 infections/person-year at risk. However, this incidence rate approximated the
known reinfection rate in this cohort (5.7 infections/person-year). Thus, the observed
parasitemia in the treatment group could be almost wholly attributed to the measured
reinfection rate in this cohort. This method has been reported previously in comparing
the efficacy of antimalarial drug regimens (13,14).
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3.2.8. Attributable Fraction
Attributable fraction represents an estimate of the risk of disease in a community
that is attributable to a particular risk factor. Because many symptoms of malaria are
non-specific, attributable fraction is a useful measure in looking at clinical markers or
case definitions for malaria in a community. The statistic assigns a probability of a
single fever episode being due to malaria. For a single exposure variable, the overall
attributable fraction is given by
AF = p(R – 1)/R
where p is the exposure prevalence among cases and R is the relative risk of disease
associated with the exposure (15). The probability that any individual case is attribut-
able to malaria is calculated without multiplying by p (16).
Probabilities derived from logistic regression models can increase the precision of
the attributable fraction estimates by allowing fever risk as a continuous function of
parasite density (16) and can be further extended to include other covariates (17).
Schellenberg et al. (18) used the fraction of fever cases in a population attributable
to malaria at each level of parasite density to evaluate the sensitivity and specificity of
alternative case definitions for malaria, and to provide a direct estimate of malaria-
attributable fever. The attributable fraction statistic also has been used to determine the
specificity and sensitivity of case-definition thresholds (19).
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